Drugs / LB-DTK-BKV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07638332 | Sep 2026 → Mar 2028 expected | hemorrhagic cystitis | LucasBio | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB-DTK-BKV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07638332 ↗ |
| Modality | Cell therapy | “efficacy of BK virus specific T cells (LB-DTK-BKV)” NCT07638332 ↗ |
| Route | Intravenous | “single intravenous infusion of LB-DTK-BKV” NCT07638332 ↗ |